Trials / Terminated
TerminatedNCT04892446
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical study is to learn more about the safety and dosing of the study drug, magrolimab, in combination with other anticancer therapies in participants with relapsed/refractory multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Magrolimab | Administered IV |
| DRUG | Daratumumab | Administered either SC or IV |
| DRUG | Pomalidomide | Administered orally |
| DRUG | Dexamethasone | Administered orally |
| DRUG | Bortezomib | Administered either SC or IV |
| DRUG | Carfilzomib | Administered IV |
Timeline
- Start date
- 2021-11-09
- Primary completion
- 2024-04-25
- Completion
- 2024-04-25
- First posted
- 2021-05-19
- Last updated
- 2025-05-02
- Results posted
- 2025-05-02
Locations
22 sites across 3 countries: United States, Canada, Czechia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04892446. Inclusion in this directory is not an endorsement.